Testosterone and Myocardial Perfusion in Coronary Heart Disease (CHD)
Coronary Heart Disease
About this trial
This is an interventional treatment trial for Coronary Heart Disease
Eligibility Criteria
Inclusion Criteria: Men Aged 35 to 75 years Angiographically proven coronary artery disease (70 percent lesion in at least one major coronary artery, or major branch), including patients post-coronary artery bypass graft (CABG) and percutaneous coronary intervention (PCI) Plasma testosterone less than or equal to 12 nmol/l Normal prostate specific antigen (PSA; normal range 0 - 4 g/l) Willing to give written informed consent Exclusion Criteria: Significant arrhythmia, particularly those which would affect interpretation of the ST-segment of the ECG Treatment with digitalis Treatment with testosterone or similar hormonal therapy Thoracic or abdominal surgery within the previous 3 months Haemoglobin >16 g/dL Haematocrit >50 percent History of hormone-dependent cancer such as prostate or breast cancer Hypercalcaemia Nephrosis Pacemaker or automated implantable cardiac defibrillator Implanted ferromagnetic arterial clips Left ventricular hypertrophy New York Heart Association (NYHA) III or IV functional class Intolerance of confined spaces Previous allergic reaction to Gadolinium Participation in another research study within the previous 60 days Unwilling to give written informed consent
Sites / Locations
- Royal Brompton & Harefield NHS Trust
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Testosterone
Placebo
oral testosterone undecanoate, 80mg twice daily (Andriol Testocaps, Organon, The Netherlands) for 8 weeks
identical to active medication, taken in an identical way to the active arm